Reducing insulin resistance with GRAS ingredients for metabolic health
Discover a novel combination of GRAS ingredients, tagatose and allulose, designed to reduce insulin resistance and blood glucose levels. Backed by pilot studies, this patent-pending solution offers a promising alternative to current treatments with fewer side effects.
Overview
DiaVita Therapeutics LLC presents an innovative solution to combat insulin resistance and manage blood glucose levels using a patent-pending combination of rare sugars, tagatose, and allulose. These Generally Recognized As Safe (GRAS) ingredients target individuals with diabetes, metabolic syndrome, and those seeking to prevent these conditions. The combination aims to provide many benefits akin to current medications like Ozempic, but without the associated side effects and costs. Preliminary pilot studies have shown promise in reducing blood sugar and promoting weight loss.
Technical specifications
Key features:
- Combination of tagatose and allulose, both recognized as GRAS
- Inhibits digestive enzymes to reduce glucose accumulation
- Induces release of gastrointestinal satiety hormones such as GLP-1
- Prebiotic effects to enhance gut health
Application:
- Targeted for individuals with type 1 and type 2 diabetes, metabolic syndrome, and those at risk
- Potential to be integrated into tasty snack formulations consumed before meals
- Continuous glucose monitoring during trials to evaluate effectiveness
Technology readiness level
This solution is at Technology Readiness Level 6, with successful pilot studies completed in pre-diabetic and type 1 diabetic populations. Future studies aim to broaden the subject pool and further validate the efficacy of the formulation across diverse demographics.
delivered to your inbox.